Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rivaroxaban × Myeloid × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 11 Gastrointestinal 3 Tumor-Agnostic 2 Thoracic 2 Plasma cell 2 Genitourinary 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 CNS 1 Breast 1

Conditions

Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 204 fludarabine phosphate 182 fludarabine 144 Busulfan 127 Mycophenolic Acid 117 Whole-Body Irradiation 116 Tacrolimus 107 Peripheral Blood Stem Cell Transplantation 103 Azacitidine 93 Cytarabine 89 Melphalan 87 Cyclosporine 87 Antilymphocyte Serum 86 Imatinib Mesylate 78 Filgrastim 75 Methotrexate 73 Decitabine 60 Granulocyte Colony-Stimulating Factor 52 thymoglobulin 50 Thiotepa 49 Stem Cell Transplantation 47 venetoclax 46 Radiotherapy 45 Cord Blood Stem Cell Transplantation 36 nilotinib 33 Methylprednisolone 33 ruxolitinib 32 Clofarabine 32 Sirolimus 31 Dasatinib 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡